MECHANISMS OF FIBROCYTE INDUCTION IN LYMPHOID MALIGNANCIES: THE ROLE OF CCL22 AND TIMP-1 IN SECONDARY MYELOFIBROSIS

EHA Library, Noriaki Tachi, 4160231

REAL WORLD PATIENT CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES FOR CHINESE PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA

EHA Library, Kaiyang Ding, 4160279

RESPONSE ADAPTED THERAPY OF PEDIATRIC CLASSIC HODGKIN LYMPHOMA ACCORDING TO MODIFIED EURO-NET PROTOCOL-SINGLE CENTER EXPERIENCE

EHA Library, Hani Abdel Rahman Sayed, 4160278

CHARACTERISTICS AND PREDICTORS OF EARLY DEATHS IN CLASSICAL HODGKIN LYMPHOMA

EHA Library, Cong Sun, 4160277

CONSOLIDATION TREATMENT WITH BRENTUXIMAB VEDOTIN AFTER ALLOGENEIC STEM-CELL TRANSPLANTATION FOR RELAPSED HODGKIN LYMPHOMA: ANALYSIS OF THE GHSG PHASE 2 BV-ALLO TRIAL

EHA Library, Christof Scheid, 4160276

PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG-TERM FOLLOW-UP OF THE GATLA LH-05 TRIAL

EHA Library, Astrid Pavlovsky, 4160275

FIVE-YEAR EXPERIENCE WITH PD-1 INHIBITOR COMBINATION REGIMENS IN REFRACTORY CLASSIC HODGKIN LYMPHOMA AFTER FAILURE OF IMMUNE CHECKPOINT INHIBITOR MONOTHERAPY

EHA Library, Julia Zhuravleva, 4160274

PROGNOSTIC VALUE OF PET/CT BEFORE AUTOLOGOUS STEM-CELL TRANSPLANTATION IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA

EHA Library, Justin Ferdinandus, 4160273

TREATMENT EFFICACY FOR ADVANCED-STAGE CLASSIC HODGKIN LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS

EHA Library, Rong Tao, 4160272

EVALUATION OF LONG-TERM OUTCOMES IN ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA TREATED WITH ABVD USING A PET-GUIDED STRATEGY

EHA Library, Jowon Laura Kim, 4160271

REAL-WORLD OUTCOMES OF PATIENT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB-VEDOTIN IN ASSOCIATION WITH BENDAMUSTINE: THE FRENCH LYSA EXPERIENCE

EHA Library, Gaétan Basile, 4160270

MYMPNVOICE APP: REMOTE LONGITUDINAL MONITORING OF PATIENT REPORTED OUTCOMES AND BIOMETRICS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Patrick Harrington, 4160269

AN OPEN-LABEL CLINICAL TRIAL OF RVU120 AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK, PRIMARY OR SECONDARY MYELOFIBROSIS (POTAMI-61).

EHA Library, Rostislav Kuklík, 4160268

ASSESSMENT OF RISK FACTORS AND ANTICOAGULATION STRATEGY IN MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (MPN-SVT): SINGLE-CENTRE, LONG-TERM, REAL-WORLD DATA.

EHA Library, Elena Torre, 4160267

CLINICAL PATHWAYS AND PROGNOSTIC STRATEGIES IN MYELOFIBROSIS: A REAL-WORLD ANALYSIS OF GERMAN PRACTICE

EHA Library, Francisco Henriquez, 4160266

RENAL FUNCTION MODERATES ASSOCIATIONS OF RED CELL MASS AND PLASMA VOLUME WITH THROMBOTIC RISK IN NEWLY DIAGNOSED POLYCYTHEMIA VERA PATIENTS

EHA Library, Danijela Lekovic, 4160265

FACTORS INFLUENCING CHR AND MR ACHIEVEMENT AND MAINTENANCE IN POLYCYTHEMIA VERA PATIENTS WITH HYDROXYUREA RESISTANCE/INTOLERANCE TREATED WITH ROPEGINTERFERON ALFA-2B

EHA Library, Sung-Eun Lee, 4160264

A PHASE 1B/2 STUDY OF DISC-0974, AN ANTI-HEMOJUVELIN ANTIBODY, IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA

EHA Library, Sima Bhatt, 4160263

THE PROGNOSTIC IMPACT OF CYTOGENETIC AND MOLECULAR TESTING IN SECONDARY MYELOFIBROSIS

EHA Library, Holly Pertile, 4160262

A REAL-WORD STUDY ON THE EFFICACY AND SAFETY OF SELINEXOR PLUS RUXOLITINIB REGIMEN IN RUXOLITINIB-RESISTANT MYELOFIBROSIS

EHA Library, Na Xu, 4160261

GECACITINIB THERAPY'S IMPACT ON SYMPTOM BURDEN IN THE ZGJAK016 STUDY

EHA Library, Yi Zhang, 4160260

RESULTS OF ALLOGENEIC STEM CELL TRANSPLANTATION IN ADVANCED MYELOFIBROSIS

EHA Library, Jong Hyuk Lee, 4160259

OPHTHALMOLOGICAL MANIFESTATIONS OF MYELOFIBROSIS AT THE ONSET AND DURING THERAPY

EHA Library, Olga Vinogradova, 4160258

GECACITINIB-INDUCED SPLEEN VOLUME REDUCTION (SVR) AND ITS PROGNOSTIC VALUE FOR OVERALL SURVIVAL (OS) IN MYELOFIBROSIS

EHA Library, Yi Zhang, 4160257

HEMATOLOGIC IMPROVEMENT EXPERIENCED BY PACRITINIB-TREATED PATIENTS WITH MYELOFIBROSIS IN REAL-WORLD CLINICAL SETTINGS

EHA Library, Michael Marrone, 4160256

SEX INFLUENCES MPN PHENOTYPE AND CLINICAL OUTCOMES: A REAL WORLD STUDY OF 1167 SUBJECTS FROM THE QUEBEC REGISTRY

EHA Library, Geneviève Huynh-Trudeau, 4160255

STUDY DESIGN AND DEMOGRAPHICS OF IMPRSSION, A PHASE 2 OPEN-LABEL CLINICAL TRIAL EVALUATING TMPRSS6 ANTISENSE INHIBITOR SAPABLURSEN, IN POLYCYTHEMIA VERA

EHA Library, Terrance Barrett, 4160254

A NEW PROGNOSTIC RISK MODEL IN POLYCYTHEMIA VERA: THE TRIPLE A MODEL

EHA Library, Eda Nuhoğlu Kantarcı, 4160253

ALPHABETA T-CELL / CD19 GRAFT DEPLETED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COMBINATION WITH POST-TRANSPLANT RUXOLITINIB FOR MYELOFIBROSIS

EHA Library, Anniek Stuut, 4160252

A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL TO ADDRESS THE IMPACT OF TARGETED FLUDARABINE ON THE INCIDENCE OF VIRAL COMPLICATIONS AFTER αßTCR/CD19 DEPLETED ALLO-HCT

EHA Library, Moniek de Witte, 4160251

PROGNOSTIC IMPLICATIONS OF RED BLOOD CELL DISTRIBUTION WIDTH-TO-ALBUMIN RATIO IN PATIENTS WITH MYELOFIBROSIS: INSIGHTS FROM A 10-YEAR RETROSPECTIVE AND MULTICENTER COHORT

EHA Library, Jian Huang, 4160250

LYMPHOCYTE TO MONOCYTE RATIO MAY PREDICT TRANSFORMATION TO MYELOFIBROSIS FOR POLYCYTHEMIA VERA PATIENTS TREATED WITH RUXOLITINIB: EXPERIENCE FROM MAJIC-PV TRIAL

EHA Library, Andrea Duminuco, 4160249

IMPACTMF, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED OR REFRACTORY TO JANUS KINASE INHIBITORS

EHA Library, John Mascarenhas, 4160248

IMPACT OF ELN CLINICAL SIGNS AND SYMPTOMS ON OUTCOMES IN POLYCYTHEMIA VERA PATIENTS TREATED WITH HYDROXYUREA OR RUXOLITINIB: A COOPERATIVE STUDY

EHA Library, Francesca Palandri, 4160247

GENE EXPLORATION AND CLINICAL CHARACTERISTICS IN TRIPLE-NEGATIVE ESSENTIAL THROMBOCYTHEMIA VIA WHOLE EXOME SEQUENCING

EHA Library, Siraphop Thammayot, 4160246

THROMBOSIS RISK AND HORMONE USE IN WOMEN WITH MPN : DATA FROM A CONTEMPORARY COHORT

EHA Library, Ikram-Nour Abda, 4160245

GECACITINIB IN JAKI-NAÏVE AND JAKI-EXPOSED MYELOFIBROSIS PATIENTS: IMPROVED TRANSFUSION INDEPENDENCE

EHA Library, Yi Zhang, 4160244

DEFINING THE PROGNOSIS FOR ESSENTIAL THROMBOCYTHEMIA: A VALIDATION OF THE AAA+A RISK MODEL AND THE IDENTIFICATION OF A NEW PROGNOSTIC MARKER, THE LYMPHOCYTES-TO-MONOCYTES RATIO

EHA Library, Fabrizio Cavalca, 4160243

SURVIVAL OUTCOMES IN ACCELERATED AND BLAST PHASE MPN: A REAL-WORLD ANALYSIS FROM THE UK MPN CLINICAL STUDY GROUP.

EHA Library, Alexandros Rampotas, 4160242

PROTECTIVE EFFECT OF ACETYLSALICYLIC ACID AND INTERFERON ALPHA ON LIVE BIRTH RATE IN MYELOPROLIFERATIVE NEOPLASMS: A META-ANALYSIS BASED ON THE SYSTEMATIC REVIEW OF 1,697 PREGNANCIES.

EHA Library, Monia Marchetti, 4160241

FINAL RESULTS OF A PILOT STUDY OF ELOTUZUMAB IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Prithviraj Bose, 4160240

TRANSCRIPTIONAL REPROGRAMMING OF SPLENIC ENDOTHELIAL CELLS IN MYELOFIBROSIS

EHA Library, Francesca Lazzaroni, 4160222

IMMUNE-MEGAKARYOCYTES ARE RESPONSIBLE FOR THE PATHOLOGICAL INTERLEUKIN-8 DEPENDENT EMPERIPOLESIS WITH NEUTROPHILS ASSOCIATED WITH MYELOFIBROSIS IN GATA1LOW MICE

EHA Library, Mario Falchi, 4160223

THE INFLAMMASOME NEGATIVELY MODULATES HEME OXYGENASE 1 CONTRIBUTING TO BONE MARROW FIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jessica Ferrigno, 4160224

HYDROXYUREA DRIVES CLONAL SELECTION OF TP53 MUTATED CELLS IN MYELOPROLIFERATIVE NEOPLASMS (MPN)

EHA Library, Nabih Maslah, 4160225

JAK2 V617F VAF AND PRESENCE OF COPY NEUTRAL-LOH AT CHROMOSOME 9P (CHR9P) PREDICTS TRANSFORMATION TO MYELOFIBROSIS (MF) IN PATIENTS WITH POLYCYTHEMIA VERA (PV) ENROLLED IN REVEAL

EHA Library, Stephen Oh, 4160226

DECODING THE SUCNR1/HIF-1α /TNF-α AXIS: HOW MONOCYTES FUEL MYELOFIBROSIS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jieyu Wang, 4160227

THE CLONAL ORIGIN AND EVOLUTION OF HIGH-RISK MULTISYSTEM HISTIOCYTOSIS IN ADULTS

EHA Library, Kudzai Nyamondo, 4160228

THROMBOCYTOPENIA IN MYELOFIBROSIS (MF) IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION THROMBOCYTOPENIA IN MYELOFIBROSIS IS CHARACTERIZED BY INFLAMMATORY MEGAKARYOCYTES WITH REDUCED G6B EXPRESSION

EHA Library, Lilian Varricchio, 4160229

THE SPATIAL DYSREGULATION OF MICROENVIRONMENT INVOLVING TENASCIN-C EXPRESSING CELLS CAN BE A CLINICALLY APPLICABLE MARKER FOR FIBROSIS PROGRESSION IN THE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS.

EHA Library, Keiki Nagaharu, 4160230

ADULT LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: CLINICAL FEATURES, DIAGNOSTIC CHALLENGES, AND TREATMENT OUTCOMES—A 24-YEAR SINGLE-CENTER RETROSPECTIVE ANALYSIS

EHA Library, Humberto Nieves-Jiménez, 4160280

TYK2 IS SPECIFICALLY ACTIVATED IN CALR-MUTANT MYELOPROLIFERATIVE NEOPLASMS AND JAK2 EXPRESSION DETERMINES ITS DRUGGABILITY

EHA Library, Nicolas Chatain, 4160232

CD44 CONTRIBUTES TO EXTRAMEDULLARY HEMATOPOIESIS IN MYELOFIBROSIS PATIENTS BY REGULATING THE INTERPLAY BETWEEN MONOCYTE AND HEMATOPOIETIC STEM AND PROGENITOR CELLS

EHA Library, Camilla Tombari, 4160233

NEW CRITERIA FOR EVALUATING OUTCOMES OF MYELOFIBROSIS THERAPY: THE EUROPEAN LEUKEMIANET DEMYOS (DESIRABILITY OF MYELOFIBROSIS OUTCOMES)

EHA Library, Monia Marchetti, 4160234

SURVIVAL IMPACT AND KINETICS OF HEMOGLOBIN IMPROVEMENT WITH MOMELOTINIB IN PATIENTS WITH MYELOFIBROSIS AND MODERATE TO SEVERE ANEMIA: POST HOC ANALYSES OF SIMPLIFY-1 AND MOMENTUM

EHA Library, Francesca Palandri, 4160235

SAFETY PROFILE OF LONG-TERM EXPOSURE TO RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS, ANALYSIS FROM A REAL-WORLD DATA NETWORK

EHA Library, Alberto Blanco Sánchez, 4160236

IMPROVEMF UPDATE: PHASE 1/1B TRIAL OF IMETELSTAT (IME)+RUXOLITINIB (RUX) IN PATIENTS WITH INTERMEDIATE (INT)-1, INT-2, OR HIGH-RISK (HR) MYELOFIBROSIS (MF)

EHA Library, John Mascarenhas, 4160237

FIBROSIS GRADE BEFORE AND ITS RESOLUTION AFTER TRANSPLANTATION HAS NO PREDICTIVE VALUE IN MYELOFIBROSIS

EHA Library, Nico Gagelmann, 4160238

THE KEY ROLE OF MONOCYTES IN THE EVOLUTION OF MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Wayne-Corentin Lambert, 4160239

VENOUS THROMBOEMBOLISM IN PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: INSIGHTS FROM REAL-WORLD DATA

EHA Library, Vladimir Otasevic, 4159396

TARGETED SUPPRESSION OF EFFECTOR T CELLS BY GPIBα CAAR-TREG CELLS IN REFRACTORY/RELAPSED IMMUNE THROMBOCYTOPENIA

EHA Library, Jinhui Shu, 4159395

MICROFLUIDIC TESTING USING THE MAASTRICHT FLOWCHAMBER IN PATIENTS WITH BLEEDING DISORDER OF UNKNOWN CAUSE (BDUC)

EHA Library, Amaury Monard, 4159394

HEPATIC PLASMINOGEN LOWERING WITH RNA INTERFERENCE FOR THE TREATMENT OF BLEEDING DISORDERS IS UNLIKELY TO POSE THROMBOTIC RISK BASED ON UK BIOBANK ANALYSES AND MOUSE MODELS OF PROVOKED THROMBOSIS

EHA Library, Rodney Camire, 4159393

BLASTS- AND MODIFIED EASIX-GUIDED RISK STRATIFICATION FOR CAR-T-ASSOCIATED COAGULOPATHY AND OUTCOMES

EHA Library, Yingying Li, 4159392

SAFETY OF HYPOXIC RED BLOOD CELL ADMINISTRATION IN PATIENTS WITH TRANSFUSION-DEPENDENT HEMATOLOGICAL MALIGNANCIES

EHA Library, Håkon Reikvam, 4159386

BLOOD GROUP GENOTYPE DIVERSITY IN SICKLE CELL DISEASE PATIENTS: ANTIGENIC PROFILE FROM A SINGLE CENTER AND SYSTEMATIC REVIEW OF THE LITERATURE

EHA Library, Luiza Francisco Trafane, 4159385

CORD RED BLOOD CELL TRANSFUSIONS IN EXTREMELY LOW GESTATIONAL AGE NEONATES TO PREVENT SEVERE ROP: RESULTS OF THE RANDOMIZED CLINICAL TRIAL BORN

EHA Library, Claudio Pellegrino, 4159384

TARGETING THE MTOR PATHWAY TO REGULATE PIEZO1-MEDIATED IRON OVERLOAD

EHA Library, Federica Maria Esposito, 4159383

IRON TRAPPING IN MACROPHAGES RESHAPES THE HOMEOSTASIS OF THE HAEMATOPOIETIC SYSTEM

EHA Library, Laura Crisafulli, 4159382

INVASIVE FUNGAL INFECTIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA: PRELIMINARY RESULTS OF A MULTICENTRIC PROSPECTIVE SEIFEM STUDY (ALL-IFI)

EHA Library, Chiara Cattaneo, 4159381

INCIDENCE AND RISK FACTORS FOR LATE CYTOMEGALOVIRUS (CMV) BLOOD INFECTIONS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLOHCT)

EHA Library, George Chen, 4159380

CHANGES IN THE SPECTRUM AND PROGNOSIS OF INVASIVE FUNGAL DISEASES IN CZECH, SLOVAK, AND CROATIAN HEMATOLOGY CENTERS FROM 2000 TO 2023 - FIND ANALYSIS

EHA Library, Barbora Weinbergerová, 4159379

LONG TERM FOLLOW UP OF THE BATMO PROTOCOL (BEST-ANTIMICROBIAL-THERAPY-TMO) AND COMPARISON WITH HYSTORICAL DATA

EHA Library, Michele Malagola, 4159378

REAL-WORLD INSIGHT ON TREATMENT WITH MARIBAVIR FOR CLINICALLY-SIGNIFICANT CMV INFECTION IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: A RETROSPECTIVE INTERNATIONAL IDWP EBMT STUDY

EHA Library, Annalisa Paviglianiti, 4159377

G-CSF IMPROVES TREG SELECTION AND OUTCOMES OF HLA-HAPLOIDENTICAL HEMATOPOIETIC CELL TRANSPLANTATION WITH T CELL ADOPTIVE IMMUNOTHERAPY

EHA Library, Rebecca Sembenico, 4159341

PHARMACOKINETIC-GUIDED ATG DOSING OPTIMIZES OUTCOMES IN MYELOABLATIVE HAPLO-CORD HCT

EHA Library, Qingya cui, 4159340

ANTI-CD25 ANTIBODY AS AN ALTERNATIVE TO METHOTREXATE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS RESULTED IN BETTER OUTCOMES IN PATIENT OF CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY BRIDGING TO TRANSPLANT

EHA Library, Zhihui Li, 4159339

AUTONOMOUS AI-DRIVEN INTENSIFIED PROPHYLAXIS OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE IN HAPLOIDENTICAL TRANSPLANTS: A SINGLE-CENTRE, PROOF-OF-CONCEPT, PHASE 2 TRIAL

EHA Library, Yigeng Cao, 4159338

POOLED FECAL ALLOGENIC MICROBIOTHERAPY FOR REFRACTORY GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE : RESULTS FROM THE EARLY ACCESS PROGRAM IN EUROPE

EHA Library, Mohamad Mohty, 4159337

SLF2, A NOVEL CAUSATIVE GENE FOR INHERITED BONE MARROW FAILURE SYNDROMES AND MDS, AND ITS SIGNIFICANCE IN HEMATOPOIETIC STEM CELL AGING AND LEUKEMIC PROGRESSION

EHA Library, Sho Shibata, 4159258

POISONING OF HEMATOPOIESIS DRIVES CLONAL DOMINANCE AND BONE MARROW FAILURE IN VEXAS SYNDROME

EHA Library, Martina Fiumara, 4159257

CHARACTERIZATION & EFFICACY OF TERN-701 IN PRE-CLINICAL MODELS OF CHRONIC MYELOID LEUKEMIA

EHA Library, Ben Parsons, 4159246

COMPARISON OF MOLECULAR RESPONSE AND SAFETY OF LOWER DOSE (70 MG) VERSUS STANDARD DOSE (100 MG) OF GENERIC DASATINIB IN NEWLY DIAGNOSED PATIENTS WITH CML-CP: RANDOMISED CONTROLLED STUDY FROM INDIA

EHA Library, Paras Satadeve, 4159245

CHRONIC MYELOID LEUKEMIA (CML) TREATMENT DISCONTINUATION AFTER A TWO-STEP DOSE REDUCTION. THE FIRST RESULTS OF THE PHASE 2 STUDY HALF.

EHA Library, Jiří Mayer, 4159244

ASCIMINIB (ASC) SHOWS SUPERIOR TOLERABILITY VS NILOTINIB (NIL) IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): PRIMARY ENDPOINT RESULTS OF THE PHASE (PH) 3B ASC4START TRIAL

EHA Library, Andreas Hochhaus, 4159243

ENABLE: A PHASE 1A/1B STUDY OF ELVN-001, A SELECTIVE ACTIVE SITE INHIBITOR OF BCR::ABL1, IN PATIENTS WITH PREVIOUSLY TREATED CML

EHA Library, Andreas Hochhaus, 4159242

PRECLINICAL EVALUATION OF ANTI-CD38 THERAPY HIGHLIGHTS CD38 AS A NOVEL IMMUNOTHERAPEUTIC TARGET FOR TREATING T-LGLL PATIENTS WITH STAT3 MUTATION

EHA Library, Giulia Calabretto, 4159231

PENTOSE PHOSPHATE PATHWAY REGULATED THROUGH IL-21 CONTROLS TUMOR PROGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Anna Kabanova, 4159230

UNVEILING RYK: A BREAKTHROUGH TUMOR-ASSOCIATED ANTIGEN IN LYMPHOMA TREATMENT

EHA Library, Matilde Micillo, 4159229

CHRONIC LYMPHOCYTIC LEUKEMIA CELLS RELY ON GLUTAMINE: IMPLICATIONS FOR THERAPY AND DIAGNOSTICS

EHA Library, Helga Simon-Molas, 4159228

CLL-LIKE EPIGENETIC AND TRANSCRIPTOMIC STATES ARE PRESENT IN LOW-COUNT MBL AS REVEALED BY SINGLE-CELL MULTI-OMICS ANALYSES

EHA Library, Anja Rathgeber, 4159227

AN IMMUNOTHERAPY FOR RAPID BONE MARROW CONDITIONING AND LEUKEMIA DEPLETION THAT ALLOWS EFFICIENT HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Milad Rasouli, 4159206

SELECTIVE ERADICATION OF AML STEM CELLS VIA LIGHT/LTBR SIGNALING INHIBITION

EHA Library, Sabine Hoepner, 4159205

SLAMF6 UPREGULATION MEDIATES IMMUNE ESCAPE AND CONSTITUTES A NOVEL TARGET FOR CHECKPOINT INHIBITION IN ACUTE MYELOID LEUKEMIA

EHA Library, Carl Sandén, 4159204

A NOVEL MODULAR CAR-T CELL THERAPY SHOWS PROMISING ADVANTAGES OVER CONVENTIONAL CAR-T CELLS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

EHA Library, Alex Joechner, 4159203

CELL-INTRINSIC INFLAMMATION SHAPES CELL-STATE HETEROGENEITY AND DRIVES THERAPEUTIC RESISTANCE IN HUMAN ACUTE MYELOID LEUKEMIA

EHA Library, Lina Liu, 4159202

FIRST-IN-HUMAN STUDY OF ASCIMINIB (ASC) MONOTHERAPY IN ADULTS WITH RELAPSED/REFRACTORY (R/R) PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL)

EHA Library, Michael Mauro, 4159196

LONG-TERM FOLLOW-UP OF AN INTENSIVE PEDIATRIC REGMEN FOR ADOLESCENTS/YOUNG ADULTS (AYA) WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): 10-YEAR SURVIVAL FOLLOWING CALGB 10403 (ALLIANCE)

EHA Library, Wendy Stock, 4159195

SAFETY AND EFFICACY OF AZD0486 IN ADOLESCENT AND ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: EARLY RESULTS FROM THE PHASE 1/2 SYRUS STUDY

EHA Library, Ibrahim Aldoss, 4159194

ADVANCING CHEMOGENOMIC STRATEGIES FOR FUNCTIONAL PRECISION MEDICINE IN RELAPSED/REFRACTORY T-ALL AND ETP-ALL: PRELIMINARY RESULTS OF THE GIMEMA ALL2720 TRIAL

EHA Library, Luca Pagliaro, 4159192